de Jager, Vincent D.
Stigt, Jos A.
Niemantsverdriet, Maarten
ter Elst, Arja
van der Wekken, Anthonie J. http://orcid.org/0000-0001-7175-0026
Article History
Received: 8 January 2024
Accepted: 8 May 2024
First Online: 22 May 2024
Competing interests
: A.v.d.W. has received grants or contracts from AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche, and Takeda, has received consulting fees from AstraZeneca, Janssen, Lilly, Roche, and Takeda, has received payments or honoraria from AstraZeneca, BMS, Lilly, Pfizer, and Roche, has a leadership or fiduciary role in the oncology section NVALT, guideline committee NSCLC and CUP, dure geneesmiddelen committee NVALT and FMS. The remaining authors declare no competing interests.